Administration of everolimus to IL-10-deficent mice, which develops spontaneous colitis, inhibits the proliferation of activated T cells, decreases the number of Th1 cells and the production of inflammatory cytokines by Th1 cells in the lamina propria, and ultimately ameliorates chronic colitis (59). This evidence concerns the gene IL10 and Chronic colitis.